Nothing said here yet.
to join the conversation.
| Gruninger MarcDirector | Buy | 9,133 | $9.1K | Wed, Oct 28 |
| Gruninger MarcDirector | Buy | 867 | $849 | Tue, Oct 27 |
| Ziegler Christoph SamuelDirector | Buy | 30,000 | $32.7K | Tue, Oct 20 |
| Hosseinion WarrenDirector | Buy | 6,024 | $10.1K | Thu, Sep 10 |
| Baumann Oliver RolfDirector | Buy | 50,000 | $75.0K | Thu, Aug 27 |
| Antz Christoph RudigerChief Executive Officer | Buy | 5,000 | $7.7K | Thu, Aug 27 |
VERAXA is implementing FDA-aligned New Approach Methodologies ("NAMs") across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports developme...
Austin, Texas, October 21st, 2026, FinanceWire VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs,...
LOS ANGELES, CA - October 13, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC tec...
LOS ANGELES, CA - October 7, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration "FDA"-aligned New Appr...
Investing.com -- Veraxa Biotech AG (NASDAQ:VRXA) shares rose 3.7% in premarket trading Wednesday following the company's announcement of a strategy to implement FDA-aligned New Approach Methodologies across its preclinical programs.
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’
LOS ANGELES, CA - September 24, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion o...
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered the NASDAQ market in June 2026 following its completed bus...